Robert Haddad, MD
Associate Professor, Department of Medicine, Harvard Medical School
Associate Professor of Medicine, Medical Oncology, Dana-Farber Cancer Institute
DF/HCC Program AffiliationHead and Neck Cancer
Dr. Haddad’s current research activity involves the use of intensive and Novel chemoradiotherapy regimens for patients with locally advanced and metastatic head and neck cancer with particular attention to radioprotection. He is also the principal investigator in a large national phase III study comparing sequential chemoradiotherapy to concomitant chemoradiotherapy: The Paradigm Trial. Other initiatives currently ongoing include collaboration with the NCI/CTEP in a phase II study looking at the use of depsipeptide in head and neck cancer, as well as looking at new molecules in head and neck cancer treatment such as Cetuximab and Zactima. Dr. Haddad lectures extensively on head and neck cancer, both on the regional, national, and international level.
View All Publications